Is Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Trading At A 49% Discount?
Ligand to Report First Quarter 2025 Financial Results on May 8, 2025
The 3.6% Return This Week Takes Ligand Pharmaceuticals' (NASDAQ:LGND) Shareholders One-year Gains to 45%
Craig-Hallum Maintains Ligand Pharmaceuticals(LGND.US) With Buy Rating
Sector Update: Health Care Stocks Softer Thursday Afternoon
Ligand Pharmaceuticals to Merge Units With Channel Therapeutics to Launch Pelthos Therapeutics
Ligand Pharmaceuticals and Channel Therapeutics Announce $50 Million Merger to Advance ZELSUVMI for Molluscum Contagiosum Treatment
Express News | Channel Therapeutics Corp - Upon Completion of Deal, Plesha to Become CEO of Combined Co and Knuettel to Become CFO
Express News | Channel Therapeutics Corp -Combined Co to Operate Under Name Pelthos Therapeutics Inc., Trade on NYSE American Exchange Under Ticker Pths
Express News | Channel Therapeutics Corp - Proposed Transaction Will Raise $50 Mln in Equity Capital
Press Release: Ligand Subsidiary Pelthos Therapeutics to Combine With Channel Therapeutics
Express News | EXCLUSIVE: Ligand Pharmaceuticals Tells Benzinga 'Ligand Is Entitled to a 13% Royalty on Worldwide Sales of ZELSUVMI'
Express News | EXCLUSIVE: Ligand Pharmaceuticals Tells Benzinga 'Proposed Transaction Will Raise $50 Million in Equity Capital and Enhance a Publicly Traded Biopharmaceutical Company Focused on Launching Pelthos' ZELSUVMI'
Express News | EXCLUSIVE: Ligand Pharmaceuticals Tells Benzinga Co's Subsidiary Pelthos Therapeutics Today Announced The Signing Of Definitive Merger Agreement To Combine With Channel Therapeutics
Demonstrating resilience under Trump's tariff threats, Johnson & Johnson (JNJ.US) raises its full-year revenue guidance.
Johnson & Johnson announced its financial results for the first quarter.
J&J Kicks off Pharma Earnings Season With Guidance Raise Amid Looming Tariffs
Analyst Sees Big Upside In Ligand's Capital-Efficient Biotech Strategy
This Ligand Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
Ligand Pharmaceuticals Analyst Ratings
Stifel Maintains Ligand Pharmaceuticals(LGND.US) With Buy Rating, Maintains Target Price $143